EP3672639
COMBINATION PRODUCT OF A BCL-2 INHIBITOR AND IBRUTINIB FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
30.7.2019EP published:
23.2.2022EP application number:
19844315.2
EPO information:
European Patent Register
Max expiry date:
29.7.2039
Title in English:
COMBINATION PRODUCT OF A BCL-2 INHIBITOR AND IBRUTINIB FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCERLanguage of the patent:
English
Timeline
Today
30.7.2019EP application
23.2.2022EP Publication
Owner
Name:
Ascentage Pharma (Suzhou) Co., Ltd.Address:
Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN
Inventor
Name:
YANG, DajunAddress:
Suzhou, Jiangsu 215000, CN
Name:
ZHAI, YifanAddress:
Suzhou, Jiangsu 215000, CN
Name:
FANG, Douglas DongAddress:
Suzhou, Jiangsu 215000, CN
Name:
WANG, GuangfengAddress:
Suzhou, Jiangsu 215000, CN
Name:
ZHAI, GuoqinAddress:
Suzhou, Jiangsu 215000, CN
Priority
Number:
201810867251Date:
31.7.2018Country:
CN
Classification
Categories:
A61K 31/519, A61K 31/496, A61K 31/635, A61K 31/662, A61K 45/06, A61K 9/00, A61K 9/08, A61K 47/10, A61K 47/20, A61P 29/00, A61P 35/00, A61P 37/06